MX375784B - Composiciones farmacéuticas que comprenden al menos un compuesto de mometasona y un componente propelente. - Google Patents
Composiciones farmacéuticas que comprenden al menos un compuesto de mometasona y un componente propelente.Info
- Publication number
- MX375784B MX375784B MX2018006799A MX2018006799A MX375784B MX 375784 B MX375784 B MX 375784B MX 2018006799 A MX2018006799 A MX 2018006799A MX 2018006799 A MX2018006799 A MX 2018006799A MX 375784 B MX375784 B MX 375784B
- Authority
- MX
- Mexico
- Prior art keywords
- mometasone
- formoterol
- solvates
- propellent
- component
- Prior art date
Links
- 229960001664 mometasone Drugs 0.000 title abstract 8
- -1 MOMETASONE COMPOUND Chemical class 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 229960002848 formoterol Drugs 0.000 abstract 7
- BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 abstract 6
- QLIIKPVHVRXHRI-CXSFZGCWSA-N mometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O QLIIKPVHVRXHRI-CXSFZGCWSA-N 0.000 abstract 6
- 239000012453 solvate Substances 0.000 abstract 6
- 239000000651 prodrug Chemical class 0.000 abstract 4
- 229940002612 prodrug Drugs 0.000 abstract 4
- 150000003839 salts Chemical class 0.000 abstract 4
- NPNPZTNLOVBDOC-UHFFFAOYSA-N 1,1-difluoroethane Chemical compound CC(F)F NPNPZTNLOVBDOC-UHFFFAOYSA-N 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 239000003380 propellant Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Otolaryngology (AREA)
- Pain & Pain Management (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Anesthesiology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1521462.0A GB2545025A (en) | 2015-12-04 | 2015-12-04 | Pharmaceutical composition |
| PCT/GB2016/053804 WO2017093755A1 (en) | 2015-12-04 | 2016-12-02 | Pharmaceutical composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2018006799A MX2018006799A (es) | 2018-11-09 |
| MX375784B true MX375784B (es) | 2025-03-07 |
Family
ID=55234449
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018006799A MX375784B (es) | 2015-12-04 | 2016-12-02 | Composiciones farmacéuticas que comprenden al menos un compuesto de mometasona y un componente propelente. |
Country Status (10)
| Country | Link |
|---|---|
| US (6) | US20180264007A1 (enExample) |
| EP (3) | EP3563832A1 (enExample) |
| JP (2) | JP6993335B2 (enExample) |
| CN (2) | CN113908164A (enExample) |
| AU (3) | AU2016364005B2 (enExample) |
| CA (1) | CA3007046C (enExample) |
| ES (1) | ES2796343T3 (enExample) |
| GB (1) | GB2545025A (enExample) |
| MX (1) | MX375784B (enExample) |
| WO (1) | WO2017093755A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2545025A (en) * | 2015-12-04 | 2017-06-07 | Mexichem Fluor Sa De Cv | Pharmaceutical composition |
| CN116898804A (zh) * | 2016-09-19 | 2023-10-20 | 墨西哥氟石股份公司 | 药物组合物 |
| JP6781831B2 (ja) * | 2016-09-19 | 2020-11-04 | メキシケム フロー エセ・ア・デ・セ・ヴェ | 医薬組成物 |
| GB2573297A (en) * | 2018-04-30 | 2019-11-06 | Mexichem Fluor Sa De Cv | Pharmaceutical composition |
| JOP20200314A1 (ar) * | 2018-06-04 | 2020-12-06 | Lupin Inc | تركيبات صيدلانية مستقرة لأجهزة إستنشاق جرعات مضغوطة معايرة الجرعة |
| FR3107039B1 (fr) * | 2020-02-07 | 2022-03-18 | Aptar France Sas | Valve doseuse avec chambre de dosage améliorée |
| WO2021165348A1 (en) * | 2020-02-20 | 2021-08-26 | Chiesi Farmaceutici S.P.A. | Pressurised metered dose inhalers comprising a buffered pharmaceutical formulation |
| CN115813935A (zh) * | 2021-09-16 | 2023-03-21 | 上海上药信谊药厂有限公司 | 药物组合物、气雾剂及其制备方法和气雾剂产生系统 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SK81197A3 (en) * | 1994-12-22 | 1997-11-05 | Astra Ab | Aerosol drug formulations, method for production thereof and its use |
| GB9904919D0 (en) * | 1999-03-03 | 1999-04-28 | Novartis Ag | Organic compounds |
| US6432415B1 (en) * | 1999-12-17 | 2002-08-13 | Axrix Laboratories, Inc. | Pharmaceutical gel and aerosol formulations and methods to administer the same to skin and mucosal surfaces |
| US20020076382A1 (en) * | 2000-08-04 | 2002-06-20 | Kaplan Leonard W. | Formulations of mometasone and a bronchodilator for pulmonary administration |
| TWI324934B (en) * | 2001-08-28 | 2010-05-21 | Schering Corp | Pharmaceutical compositions for the treatment of asthma |
| GB0207906D0 (en) * | 2002-04-05 | 2002-05-15 | 3M Innovative Properties Co | Formoterol and mometasone aerosol formulations |
| GB0323684D0 (en) * | 2003-10-09 | 2003-11-12 | Jagotec Ag | Improvements in or relating to organic compounds |
| EP2444080A3 (en) * | 2007-02-09 | 2012-05-02 | Schering Corporation | Stable Pharmaceutical Drug Aerosols |
| US8236786B2 (en) * | 2008-08-07 | 2012-08-07 | Pulmagen Therapeutics (Inflammation) Limited | Respiratory disease treatment |
| GB2465897B (en) * | 2008-08-07 | 2011-02-09 | Argenta Discovery Ltd | Respiratory disease treatment |
| US20120252824A1 (en) * | 2009-06-16 | 2012-10-04 | John Brew | Drug Combinations and Uses in Treating a Coughing Condition |
| US20120238559A1 (en) * | 2009-12-03 | 2012-09-20 | Glaxo Group Limited | Novel compounds |
| WO2011076843A2 (en) * | 2009-12-23 | 2011-06-30 | Chiesi Farmaceutici S.P.A. | Combination therapy for copd |
| CN102416179B (zh) * | 2010-09-28 | 2014-05-07 | 益得生物科技股份有限公司 | 用于哮喘的吸入性复方组合物 |
| GB201108039D0 (en) * | 2011-05-13 | 2011-06-29 | Mexichem Amanco Holding Sa | Compositions |
| GB201117619D0 (en) * | 2011-10-12 | 2011-11-23 | Mexichem Amanco Holding Sa | Compositions |
| GB201117621D0 (en) * | 2011-10-12 | 2011-11-23 | Mexichem Amanco Holding Sa | Compositions |
| WO2014016548A2 (en) * | 2012-07-27 | 2014-01-30 | Cipla Limited | Pharmaceutical composition |
| BR112016014583B1 (pt) * | 2013-12-30 | 2022-12-20 | Chiesi Farmaceutici S.P.A | Composição de solução farmacêutica em aerossol, inalador pressurizado de dose calibrada e uso da dita composição |
| CN108289843B (zh) * | 2015-12-04 | 2021-08-17 | 墨西哥氟石股份公司 | 药物组合物 |
| GB2545025A (en) * | 2015-12-04 | 2017-06-07 | Mexichem Fluor Sa De Cv | Pharmaceutical composition |
| US10792256B2 (en) * | 2016-09-19 | 2020-10-06 | Mexichem Fluor S.A. De C.V. | Pharmaceutical composition |
-
2015
- 2015-12-04 GB GB1521462.0A patent/GB2545025A/en not_active Withdrawn
-
2016
- 2016-12-02 WO PCT/GB2016/053804 patent/WO2017093755A1/en not_active Ceased
- 2016-12-02 CN CN202111072725.8A patent/CN113908164A/zh active Pending
- 2016-12-02 EP EP19178833.0A patent/EP3563832A1/en active Pending
- 2016-12-02 ES ES16823027T patent/ES2796343T3/es active Active
- 2016-12-02 EP EP16823027.4A patent/EP3383367B1/en active Active
- 2016-12-02 CN CN201680071093.4A patent/CN108289842B/zh active Active
- 2016-12-02 AU AU2016364005A patent/AU2016364005B2/en active Active
- 2016-12-02 MX MX2018006799A patent/MX375784B/es active IP Right Grant
- 2016-12-02 CA CA3007046A patent/CA3007046C/en active Active
- 2016-12-02 US US15/781,060 patent/US20180264007A1/en not_active Abandoned
- 2016-12-02 JP JP2018529067A patent/JP6993335B2/ja active Active
- 2016-12-02 EP EP19178815.7A patent/EP3563831A1/en not_active Withdrawn
-
2019
- 2019-03-05 AU AU2019201520A patent/AU2019201520C1/en active Active
- 2019-03-05 AU AU2019201521A patent/AU2019201521B2/en active Active
- 2019-09-09 US US16/565,226 patent/US20190388438A1/en not_active Abandoned
- 2019-09-09 US US16/565,217 patent/US20200000826A1/en not_active Abandoned
- 2019-12-23 JP JP2019231998A patent/JP6993398B2/ja active Active
-
2022
- 2022-09-14 US US17/944,666 patent/US20230029174A1/en active Pending
- 2022-09-14 US US17/944,637 patent/US20230029180A1/en active Pending
- 2022-10-19 US US17/969,250 patent/US20230051849A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| BR112018011269A2 (pt) | 2018-11-21 |
| WO2017093755A1 (en) | 2017-06-08 |
| JP6993335B2 (ja) | 2022-01-13 |
| US20230029174A1 (en) | 2023-01-26 |
| AU2016364005A1 (en) | 2018-06-21 |
| EP3563832A1 (en) | 2019-11-06 |
| CN108289842B (zh) | 2021-10-22 |
| US20230051849A1 (en) | 2023-02-16 |
| US20180264007A1 (en) | 2018-09-20 |
| US20230029180A1 (en) | 2023-01-26 |
| US20190388438A1 (en) | 2019-12-26 |
| MX2018006799A (es) | 2018-11-09 |
| AU2016364005B2 (en) | 2019-09-26 |
| EP3383367A1 (en) | 2018-10-10 |
| CN108289842A (zh) | 2018-07-17 |
| GB201521462D0 (en) | 2016-01-20 |
| CA3007046A1 (en) | 2017-06-08 |
| CA3007046C (en) | 2021-05-11 |
| AU2019201520A1 (en) | 2019-03-28 |
| EP3383367B1 (en) | 2020-03-25 |
| GB2545025A (en) | 2017-06-07 |
| CN113908164A (zh) | 2022-01-11 |
| AU2019201521A1 (en) | 2019-03-28 |
| AU2019201520C1 (en) | 2020-12-10 |
| AU2019201520B2 (en) | 2020-07-09 |
| JP2020073514A (ja) | 2020-05-14 |
| JP2019503997A (ja) | 2019-02-14 |
| JP6993398B2 (ja) | 2022-01-13 |
| AU2019201521B2 (en) | 2020-07-16 |
| ES2796343T3 (es) | 2020-11-26 |
| EP3563831A1 (en) | 2019-11-06 |
| US20200000826A1 (en) | 2020-01-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2018006800A (es) | Composicion farmaceutica. | |
| MX375784B (es) | Composiciones farmacéuticas que comprenden al menos un compuesto de mometasona y un componente propelente. | |
| CR20160538A (es) | Combinación | |
| MX2020005063A (es) | Inhibidores de kras g12c. | |
| MX392213B (es) | Composiciones farmacéuticas que comprenden sales de glicopirrolato y 1,1-difluoroetano. | |
| ZA201902051B (en) | Pharmaceutical composition | |
| MX2021010022A (es) | Composicion farmaceutica. | |
| IL283938B1 (en) | History of oxypyrimidinyl-methyl-benzamide and their deuterated forms and pharmaceutical preparations containing them | |
| ZA201902052B (en) | Pharmaceutical composition | |
| MX386732B (es) | Composición farmacéutica de corticosteroide soluble. | |
| EP3773900A4 (en) | HINOKITIOL ANALOGUES, PROCESSES FOR THE PREPARATION AND PHARMACEUTICAL COMPOSITIONS THEREOF | |
| EP3897593A4 (en) | CANNABINOID FORMULATIONS AND PHARMACEUTICAL COMPOSITIONS | |
| MX2020005266A (es) | Regimen de cladribina para usarse en el tratamiento de formas progresivas de esclerosis multiple. | |
| CY1123408T1 (el) | Φαρμακευτικες συνθεσεις και χρηση των αυτων | |
| CO2018014217A2 (es) | Composiciones farmacéuticas que comprenden safinamida | |
| IL283105A (en) | Combination of MCL-1 inhibitor and midostearoin, its uses and pharmaceutical preparations | |
| MA45718A (fr) | Combinaison d'un inhibiteur de bcl-2 et d'un inhibiteur de mcl-1, utilisations et compositions pharmaceutiques associées | |
| IL267791B (en) | Combination of mcl-1 inhibitor and taxane compound, its uses and pharmaceutical preparations | |
| EA201991007A1 (ru) | Твердые фармацевтические композиции на основе гидрохлорида луразидона для перорального применения | |
| MX2020004403A (es) | Composiciones farmaceuticas que comprenden safinamida. | |
| MX2019000977A (es) | Composiciones farmacéuticas a base de curcumina y procedimientos para su fabricación. | |
| TN2016000561A1 (en) | Stabilized desmopressin | |
| HK40052632A (en) | Methods and compositions for delivery of agents across the blood-brain barrier | |
| HK1249055A1 (zh) | 用作药物的他喹莫德或其药学上可接受的盐与pd-1和/或pd-l1抑制剂的组合 | |
| TR201821106A2 (tr) | Meti̇l paraben ve propi̇l parabensi̇z aseti̇lsi̇stei̇n i̇çeren farmasöti̇k bi̇leşi̇m |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |